纳多洛尔和普萘洛尔对肾功能中度受损高血压患者肾功能的影响。
Effects of nadolol and propranolol on renal function in hypertensive patients with moderately impaired renal function.
作者信息
Pun K K, Yeung C K, Chan M K
出版信息
Br J Clin Pharmacol. 1985 Oct;20(4):401-4. doi: 10.1111/j.1365-2125.1985.tb05084.x.
Effects of oral administration of equipotent antihypertensive doses of propranolol and nadolol on renal function were examined in 20 hypertensive patients with moderately impaired renal function. Creatinine clearance increased, and serum beta 2-microglobulin concentrations decreased, when patients were switched from propranolol to nadolol therapy (creatinine clearance = 46.7 +/- 4.9 ml min-1 on propranolol and 52.7 +/- 5.9 on nadolol; beta 2-microglobulin = 6.14 +/- 0.66 mg l-1 on propranolol and 5.62 +/- 0.62 on nadolol). When patients were put back on propranolol, their creatinine clearances (45.9 +/- 5.0 ml min-1) and serum beta 2-microglobulin concentrations (6.51 +/- 0.67 mg l-1) returned to values comparable to those obtained before the change to nadolol was made. Serum beta 2-microglobulin concentrations correlated significantly with creatinine clearance (r = -0.819, P less than 0.001).
在20例肾功能中度受损的高血压患者中，研究了口服等效降压剂量的普萘洛尔和纳多洛尔对肾功能的影响。当患者从普萘洛尔治疗转换为纳多洛尔治疗时，肌酐清除率增加，血清β2-微球蛋白浓度降低（普萘洛尔治疗时肌酐清除率=46.7±4.9 ml/min，纳多洛尔治疗时为52.7±5.9；普萘洛尔治疗时β2-微球蛋白=6.14±0.66 mg/l，纳多洛尔治疗时为5.62±0.62）。当患者重新使用普萘洛尔时，他们的肌酐清除率（45.9±5.0 ml/min）和血清β2-微球蛋白浓度（6.51±0.67 mg/l）恢复到与改用纳多洛尔之前相当的值。血清β2-微球蛋白浓度与肌酐清除率显著相关（r=-0.819，P<0.001）。
Zotero 插件